

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	To be assigned
Filing Date	January 15, 2004
First Named Inventor	Pype et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2676-4555.1US

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SWL		#WO 96/16665	06-06-1996	La Jolla Cancer Research Foundation		
		#WO 96/18639	06-20-1996	The John Hopkins University School of Medicine		
		#WO 96/34473	09-25-1997	Trustees of Columbia University		
		#WO 97/34946	08-13-1998	Massachusetts Institute of Technology		
		#JP 11-75856	03-23-1999	Nippon Shoji KK		
		#WO 99/33869	07-08-1999	Corixa Corporation		
SWL		#WO 99/55859	11-04-1999	Vlaams Interuniversitair Instituut voor Biotechnologie VZW		

Examiner
SignatureDate
Considered

7/26/05


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned
		Filing Date	January 15, 2004
		First Named Inventor	Pype et al.
		Group Art Unit	To be assigned
		Examiner Name	To be assigned
		Attorney Docket Number	2676-4555 IUS
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SWL		#Abstract XP-002115104, Pype et al., 3.13 "Identification of a Novel CD40 Interacting Protein", 1 page.	
		#Abstract XP-002115105, Derwent Publications Ltd., "New Topoisomerase II-binding protein - useful as an anticancer agent", 1 page.	
		#HANISSIAN et al., "Jak3 Is Associated with CD40 and is Critical for CD40 Induction of Gene Expression in B Cells", Immunity, Vol. 5, pp. 379-387, April, 1997.	
		#PCT International Search Report, PCT/EP99/03025, dated September 30, 1999, 8 pages.	
		#PCT International Preliminary Examination Report, PCT/EP99/03025, dated July 24, 2000.	
		#ROTHE et al., "A Novel Family of Putative Signal Transducers Associated with the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor", Cell, Vol. 78, pp. 681-692, August 26, 1994.	
		#YANG et al., "Daxx, a Novel Fas-Binding Protein That Activates JNK and Apoptosis", Cell, Vol. 89, pp. 1067-1076, June 27, 1997	
		#GELIBERT et al., The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily, 1998, J. Biol. Chem. pp. 34120-27, Vol. 273.	
		#HONIG, B, Protein folding: from the levinthal paradox to structure prediction, 1999, J. Mol. Biol., pp. 283-93, Vol. 293.	
SWL		#GREEN et al., Identification of a novel vertebrate circadian clock-regulated gene encoding the protein nocturnin, 1996, Proc. Natl. Acad. Sci., pp. 14884-88, Vol. 93, USA.	

Examiner Signature		Date Considered	2/26/05
--------------------	-------------------------------------------------------------------------------------	-----------------	---------

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/697,863

Filed: October 27, 2000

For: CD40-Interacting and Traf-Interacting Proteins, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.